{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,21]],"date-time":"2026-09-21T17:27:15Z","timestamp":1790011635391,"version":"4.0.1"},"reference-count":35,"publisher":"Elsevier BV","issue":"11","license":[{"start":{"date-parts":[[2022,11,1]],"date-time":"2022-11-01T00:00:00Z","timestamp":1667260800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,11,1]],"date-time":"2022-11-01T00:00:00Z","timestamp":1667260800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/501100001411","name":"Indian Council of Medical Research","doi-asserted-by":"publisher","award":["5\/4\/5-7\/Diab.16-NCD-II"],"award-info":[{"award-number":["5\/4\/5-7\/Diab.16-NCD-II"]}],"id":[{"id":"10.13039\/501100001411","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Diabetes & Metabolic Syndrome: Clinical Research & Reviews"],"published-print":{"date-parts":[[2022,11]]},"DOI":"10.1016\/j.dsx.2022.102637","type":"journal-article","created":{"date-parts":[[2022,10,8]],"date-time":"2022-10-08T02:12:22Z","timestamp":1665195142000},"page":"102637","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":12,"title":["Bladder cancer with pioglitazone: A case\u2013control study"],"prefix":"10.1016","volume":"16","author":[{"given":"Bhanu","family":"Malhotra","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Priya","family":"Hiteshi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Persis","family":"Khalkho","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ritu","family":"Malik","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sanjay Kumar","family":"Bhadada","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anil","family":"Bhansali","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nusrat","family":"Shafiq","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sameer","family":"Malhotra","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Narendra","family":"Kumar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rajesh","family":"Rajput","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9375-3102","authenticated-orcid":false,"given":"Ashu","family":"Rastogi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"7","key":"10.1016\/j.dsx.2022.102637_bib1","doi-asserted-by":"crossref","first-page":"1107","DOI":"10.1007\/s00125-019-4909-y","article-title":"Type 2 diabetes: a multifaceted disease","volume":"62","author":"Pearson","year":"2019","journal-title":"Diabetologia"},{"key":"10.1016\/j.dsx.2022.102637_bib2","doi-asserted-by":"crossref","first-page":"1103","DOI":"10.1677\/ERC-09-0087","article-title":"Diabetes and cancer","volume":"16","author":"Vigneri","year":"2009","journal-title":"Endocr Relat Cancer"},{"key":"10.1016\/j.dsx.2022.102637_bib3","doi-asserted-by":"crossref","first-page":"1674","DOI":"10.2337\/dc10-0666","article-title":"Diabetes and cancer: a consensus report","volume":"33","author":"Giovannucci","year":"2010","journal-title":"Diabetes Care"},{"key":"10.1016\/j.dsx.2022.102637_bib4","doi-asserted-by":"crossref","first-page":"3295","DOI":"10.2147\/CMAR.S200059","article-title":"The beneficial effects of metformin on cancer prevention and therapy: a comprehensive review of recent advances","volume":"11","author":"Saraei","year":"2019","journal-title":"Cancer Manag Res"},{"key":"10.1016\/j.dsx.2022.102637_bib5","doi-asserted-by":"crossref","unstructured":"Chang CH, Lin JW, Wu LC, Lai MS, Chuang LM. Oral insulin secretagogues, insulin, and cancer risk in type 2 diabetes mellitus. J ClinEndocrinolMetabol2012; 97(7): E1170\u2013E1175.","DOI":"10.1210\/jc.2012-1162"},{"issue":"6","key":"10.1016\/j.dsx.2022.102637_bib6","doi-asserted-by":"crossref","first-page":"679","DOI":"10.1021\/tx034033e","article-title":"Smith. Mechanisms of troglitazone hepatotoxicity","volume":"16","author":"Martyn","year":"2003","journal-title":"Chem Res Toxicol"},{"key":"10.1016\/j.dsx.2022.102637_bib7","doi-asserted-by":"crossref","first-page":"2457","DOI":"10.1056\/NEJMoa072761","article-title":"Effect of rosiglitazone on the risk of myocardial infarction and death from cardiovascular causes","volume":"356","author":"Steven","year":"2007","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.dsx.2022.102637_bib8","doi-asserted-by":"crossref","first-page":"1279","DOI":"10.1016\/S0140-6736(05)67528-9","article-title":"PROactive investigators. Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspectivepioglitAzone Clinical Trial in macroVascular Events): a randomised controlled trial","volume":"366","author":"Dormandy","year":"2005","journal-title":"Lancet"},{"issue":"4","key":"10.1016\/j.dsx.2022.102637_bib9","doi-asserted-by":"crossref","first-page":"1070","DOI":"10.1002\/cam4.1354","article-title":"Pioglitazone and bladder cancer risk: a systematic review and meta-analysis","volume":"7","author":"Tang","year":"2018","journal-title":"Cancer Med"},{"issue":"Supplement_1","key":"10.1016\/j.dsx.2022.102637_bib10","first-page":"S111","article-title":"Pharmacologic approaches to glycemic treatment","volume":"44","year":"2021","journal-title":"Standards of Medical Care in Diabetes\u20142021 Diabetes Care"},{"issue":"2","key":"10.1016\/j.dsx.2022.102637_bib11","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1016\/j.cll.2012.04.012","article-title":"Type 2 diabetes in asian Indians","volume":"32","author":"Joshi","year":"2012","journal-title":"Clin Lab Med"},{"key":"10.1016\/j.dsx.2022.102637_bib12","doi-asserted-by":"crossref","first-page":"1945","DOI":"10.2165\/11538100-000000000-00000","article-title":"Efficacy and tolerability of pioglitazone in patients with type 2 diabetes mellitus: comparison with other oral antihyperglycaemic agents","volume":"70","author":"Derosa","year":"2010","journal-title":"Drugs"},{"key":"10.1016\/j.dsx.2022.102637_bib13","first-page":"S185","article-title":"Standards of medical care in diabetes 2022","volume":"45","author":"Retinopathy","year":"2021","journal-title":"Diabetes Care"},{"issue":"4","key":"10.1016\/j.dsx.2022.102637_bib14","doi-asserted-by":"crossref","first-page":"923","DOI":"10.2337\/dc10-1067","article-title":"Cohort study of pioglitazone and cancer incidence in patients with diabetes","volume":"34","author":"Ferrara","year":"2011","journal-title":"Diabetes Care"},{"key":"10.1016\/j.dsx.2022.102637_bib15","doi-asserted-by":"crossref","first-page":"2009","DOI":"10.1007\/s00125-011-2171-z","article-title":"Diabetes and risk of bladder cancer: a study using the National Health Insurance database in Taiwan","volume":"54","author":"Tseng","year":"2011","journal-title":"Diabetologia"},{"key":"10.1016\/j.dsx.2022.102637_bib16","first-page":"2538","article-title":"Pioglitazone and risk of bladder cancer among diabetic patients in France: a population-based cohort study","author":"Neumann","year":"2012","journal-title":"Diabetologia"},{"key":"10.1016\/j.dsx.2022.102637_bib17","doi-asserted-by":"crossref","first-page":"e3645","DOI":"10.1136\/bmj.e3645","article-title":"The use of pioglitazone and the risk of bladder cancer in people with type 2 diabetes: nested case-control study","volume":"344","author":"Azoulay","year":"2012","journal-title":"BMJ"},{"issue":"18","key":"10.1016\/j.dsx.2022.102637_bib18","doi-asserted-by":"crossref","first-page":"1411","DOI":"10.1093\/jnci\/djs328","article-title":"Association between longer therapy with thiazolidinediones and risk of bladder cancer: a cohort study","volume":"104","author":"Mamtani","year":"2012","journal-title":"J\u00a0Natl Cancer Inst"},{"issue":"1","key":"10.1016\/j.dsx.2022.102637_bib19","first-page":"63","article-title":"Observational follow-up of the PROactive study: a 6-year update","volume":"16","author":"Erdmann","year":"2014","journal-title":"Diabetes ObesMetab"},{"key":"10.1016\/j.dsx.2022.102637_bib20","doi-asserted-by":"crossref","first-page":"916","DOI":"10.2337\/dc10-1068","article-title":"Risk of bladder cancer among diabetic patients treated with pioglitazone: interim report of a longitudinal cohort study","volume":"34","author":"Lewis","year":"2011","journal-title":"Diabetes Care"},{"issue":"3","key":"10.1016\/j.dsx.2022.102637_bib21","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1001\/jama.2015.7996","article-title":"Pioglitazone use and risk of bladder cancer and other common cancers in persons with diabetes","volume":"314","author":"Lewis","year":"2015","journal-title":"JAMA"},{"issue":"1","key":"10.1016\/j.dsx.2022.102637_bib22","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1111\/j.1365-2125.2012.04325.x","article-title":"Pioglitazone and bladder cancer: a propensity score matched cohort study","volume":"75","author":"Wei","year":"2013","journal-title":"Br J Clin Pharmacol"},{"issue":"5","key":"10.1016\/j.dsx.2022.102637_bib23","doi-asserted-by":"crossref","first-page":"672","DOI":"10.4103\/ijmr.IJMR_650_15","article-title":"Pioglitazone utilization, efficacy & safety in Indian type 2 diabetic patients: a systematic review & comparison with European Medicines Agency Assessment Report","volume":"144","author":"Pai","year":"2016","journal-title":"Indian J Med Res"},{"key":"10.1016\/j.dsx.2022.102637_bib24","first-page":"79","article-title":"Prescribing pattern and efficacy of anti-diabetic drugs in maintaining optimal glycemic levels in diabetic patients","volume":"5","author":"Agarwal","year":"2014","journal-title":"J\u00a0Basic Clin Pharm"},{"issue":"1","key":"10.1016\/j.dsx.2022.102637_bib25","doi-asserted-by":"crossref","first-page":"8565","DOI":"10.1038\/s41598-019-45014-4","article-title":"Association between blood pressure and risk of cancer development: a systematic review and meta-analysis of observational studies","volume":"9","author":"Seretis","year":"2019","journal-title":"Sci Rep"},{"issue":"4","key":"10.1016\/j.dsx.2022.102637_bib26","doi-asserted-by":"crossref","first-page":"1431","DOI":"10.1002\/cam4.3721","article-title":"Association between blood pressure and BMI with bladder cancer risk and mortality in 340,000 men in three Swedish cohorts","volume":"10","author":"Teleka","year":"2021","journal-title":"Cancer Med"},{"issue":"2","key":"10.1016\/j.dsx.2022.102637_bib27","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1080\/03009734.2018.1473534","article-title":"Positive association between hypertension and urinary bladder cancer: epidemiologic evidence involving 79,236 propensity score-matched individuals","volume":"123","author":"Kok","year":"2018","journal-title":"Upsala J Med Sci"},{"key":"10.1016\/j.dsx.2022.102637_bib28","first-page":"5059","article-title":"Renin angiotensin system deregulation as renal cancer risk factor","volume":"14","author":"Sobczuk","year":"2017","journal-title":"Oncol Lett"},{"issue":"4","key":"10.1016\/j.dsx.2022.102637_bib29","first-page":"357","article-title":"Association between pioglitazone and diabetic macular edema","volume":"117","author":"Hoshikawa","year":"2013","journal-title":"Nippon Ganka Gakkai Zasshi"},{"key":"10.1016\/j.dsx.2022.102637_bib30","article-title":"Prevalent vascular complications in people with diabetes: a multicentre observational cohort study","author":"Malhotra","year":"2021","journal-title":"Int J Diabetes Dev Ctries"},{"issue":"1","key":"10.1016\/j.dsx.2022.102637_bib31","doi-asserted-by":"crossref","first-page":"40","DOI":"10.4103\/ijem.IJEM_646_18","article-title":"Drug prescription patterns and cost analysis of diabetes therapy in India: audit of an endocrine practice","volume":"23","author":"Singla","year":"2019","journal-title":"Indian J Endocrinol Metab"},{"issue":"5","key":"10.1016\/j.dsx.2022.102637_bib32","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1111\/j.1464-5491.2006.01843.x","article-title":"Effect of pioglitazone on insulin sensitivity, vascular function and cardiovascular inflammatory markers in insulin-resistant non-diabetic Asian Indians","volume":"23","author":"Raji","year":"2006","journal-title":"Diabet Med"},{"key":"10.1016\/j.dsx.2022.102637_bib33","doi-asserted-by":"crossref","first-page":"1561","DOI":"10.1001\/jama.299.13.1561","article-title":"Comparison of pioglitazone vs glimepiride on progression of coronary atherosclerosis in patients with type 2 diabetes: the PERISCOPE randomized controlled trial","volume":"299","author":"Nissen","year":"2008","journal-title":"JAMA"},{"key":"10.1016\/j.dsx.2022.102637_bib34","doi-asserted-by":"crossref","first-page":"1321","DOI":"10.1056\/NEJMoa1506930","article-title":"Pioglitazone after ischemic stroke or transient ischemic attack","volume":"374","author":"Kernan","year":"2016","journal-title":"New Engl Med"},{"issue":"2","key":"10.1016\/j.dsx.2022.102637_bib35","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1177\/1479164118825376","article-title":"the forgotten, cost-effective cardioprotective drug for type 2 diabetes","volume":"16","author":"DeFronzo","year":"2019","journal-title":"DiabVasc Dis Res"}],"container-title":["Diabetes & Metabolic Syndrome: Clinical Research & Reviews"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S187140212200251X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S187140212200251X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,29]],"date-time":"2025-10-29T09:20:16Z","timestamp":1761729616000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S187140212200251X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,11]]},"references-count":35,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2022,11]]}},"alternative-id":["S187140212200251X"],"URL":"https:\/\/doi.org\/10.1016\/j.dsx.2022.102637","relation":{},"ISSN":["1871-4021"],"issn-type":[{"value":"1871-4021","type":"print"}],"subject":[],"published":{"date-parts":[[2022,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Bladder cancer with pioglitazone: A case\u2013control study","name":"articletitle","label":"Article Title"},{"value":"Diabetes & Metabolic Syndrome: Clinical Research & Reviews","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.dsx.2022.102637","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 Diabetes India. Published by Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"102637"}}